Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.

M, Shimizu; K, Suzuki; K, Kato; T, Jojima; T, Iijima; T, Murohisa; M, Iijima; H, Takekawa; I, Usui; H, Hiraishi; Y, Aso

doi:10.1111/dom.13520

Public

Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Shared by NobleBlocks on Oct 2, 2018 • 12:00 AM UTC

Authors:

Shimizu M

Suzuki K

Kato K

Abstract

<h4>Aims</h4>To investigate the effects of dapagliflozin on liver steatosis and fibrosis evaluated in patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).<h4>Materials and methods</h4>In a randomized, active-controlled, open-label trial, 57 patients with type 2 diabetes and N...

Subject

Liver fibrosis

Type 2 diabetes

Non-alcoholic fatty liver disease

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!